Oxford Spin-Out OMass Raises $298M to Push Small-Molecule Drugs Forward

Jan de Vries · 2026-10-16

You know how some drug targets seem impossible to hit? OMass Therapeutics just got a big vote of confidence to prove otherwise. The UK biotech, a spin-out from Oxford University, closed an oversubscribed $298 million (€275 million) Series C round. That's a lot of faith in a company that's only eight years old. The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences also joined in. And every existing investor came back for more, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. ### Why This Matters OMass isn't your typical biotech. It was founded in 2016 to translate native mass spectrometry research from Professor Dame Carol Robinson's lab into new medicines. Their OdyssION platform combines next-gen native mass spectrometry, novel biochemistry, and custom chemistry. In plain English: they can study drug targets in their natural environment, giving them cell-system fidelity with cell-free precision. That's a mouthful, but it means they can tackle targets that have historically been hard to drug. "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow," says Ros Deegan, CEO of OMass Therapeutics. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic." ### The Big Bet: OMS1620 The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist. It's being developed for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. The company plans to push it through Phase 2 clinical development. If successful, it could offer a new option for patients with significant unmet needs. "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs," adds Evan Greif, Principal at Bain Capital Life Sciences. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH." ### A Hot Streak for European Biotech OMass' round is part of a broader wave of European therapeutics funding in 2026. Here's a quick look at some other notable raises: - **Bionyra Pharma** (France): $155 million for inflammatory diseases - **Breye Therapeutics** (Denmark): $73 million for oral small-molecule pipeline, also co-led by Novo Holdings - **STORM Therapeutics** (UK): $51.5 million - **Microbiotica** (UK): $45.5 million - **Mironid** (UK): $43.3 million - **Alchemab Therapeutics** (UK): $31.8 million - **Laigo Bio** (Netherlands): additional $6 million All together, these deals represent about $406 million in new financing during 2026, or $704 million when you include OMass' round. That's serious money flowing into European biotech. ### What's Next for OMass? The proceeds will support OMS1620 through Phase 2 trials for CAH and Cushing's syndrome. The company also has an SLC15A4 inhibitor in the pipeline that's poised to follow. With this raise, OMass has the resources to turn its science into real medicines. "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic," says Max Klement, Partner at Novo Holdings. "Each of these candidates has the potential to address substantial unmet patient needs." For those of us watching the European startup scene, OMass is a name to remember. And if they succeed, it could mean new treatments for patients who've been waiting a long time.